Everyone re-invents the wheel

Michael Collasius, Vice President Automated Systems Qiagen NV, on industry-wide standards for laboratory instruments

 

tl_files/images/images_we_own/b2bio content/photo library/editorial content/B2Bio100217_Collasius2_Qiagen_print.gifFebruary 2010. A major issue for manufacturers of automated screening systems resp. laboratory instruments is establishing standards across single product lines and beyond in-house solutions. Michael Collasius, Vice President Automated Systems Qiagen NV, discussed with B2Bioworld the industry challenges.

 

 

 

 

Related Articles

Customs Sequencing Markets

Worldwide evolution of the market and upcoming business opportunities

Handling Suppliers of Mass Spectrometers Delicately.

Michael P. Myers tells how tells, how he is avoiding to get trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats.

We need the users, and users have to adopt it.

Oscar-Werner Reif: A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing.

Thermo Fisher’s BRIMS-strategy.

Translating fishing expeditions into targeted assays.

Thermo Fisher benefits from growing demand for mass spectrometry in clinical biomarker research. Still, nagging questions by competitors and end-users remain.



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 3 pages

Go back

EXCLUSIVE STEM CELLS COLLECTION

Stem Cell Insights Collection 2010

Top 10 Tags

All Tags (2094)